Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP103 vs Cystagon in Nephropathic Cystinosis
NCT01000961Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2010
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of cysteamine in nephropathic cystinosis (2 arms), sponsored by Amgen. Primary endpoint: Steady-state White Blood Cell Cystine Levels. Started Jun 2010; status: completed.
02
Drugs
cysteamine
03
Conditions
nephropathic cystinosis
Beyond the preview
Go deeper on NCT01000961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01000961.